Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Anidulafungin (Ecalta®) is recommended as an option for use within NHS Wales within its licensed indication for the treatment of invasive candidiasis in adult non-neutropenic patients. AWMSG is of the opinion that anidulafungin (Ecalta®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | anidulafungin (Ecalta®) | |
| Formulation | 100 mg powder for concentrate for solution for infusion | |
| Reference number | 345 | |
| Indication | Treatment of invasive candidiasis in adult non-neutropenic patients |
|
| Company | Pfizer Ltd | |
| BNF chapter | Infections | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 0809 | |
| NMG meeting date | 25/03/2009 | |
| AWMSG meeting date | 29/04/2009 | |
| Ratification by Welsh Government | 10/06/2009 | |
| Date of issue | 11/06/2009 | |